The research agenda for improving health policy, systems performance, and service delivery for tuberculosis control: a WHO perspective. by Nunn, Paul et al.
Nunn, P; Harries, A; Godfrey-Faussett, P; Gupta, R; Maher, D; Rav-
iglione, M (2002) The research agenda for improving health policy,
systems performance, and service delivery for tuberculosis control:
a WHO perspective. Bulletin of the World Health Organization, 80
(6). pp. 471-6. ISSN 0042-9686
Downloaded from: http://researchonline.lshtm.ac.uk/16675/
DOI:
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Copyright the publishers
The research agenda for improving health policy, systems
performance, and service delivery for tuberculosis control:
a WHO perspective
Paul Nunn,1 Anthony Harries,2 Peter Godfrey-Faussett,3 Raj Gupta,1 Dermot Maher,1 & Mario Raviglione1
Abstract The development of WHO’s DOTS strategy for the control of tuberculosis (TB) in 1995 led to the expansion, adaptation and
improvement of operational research in this area. From being a patchwork of small-scale studies concerned with aspects of service
delivery, TB operational research shifted to larger-scale, often multicountry projects that were also concerned with health policy and the
needs of health systems. The results are now being put into practice by national TB control programmes. In 1998 an ad hoc committee
identified the chief factors inhibiting the expansion of DOTS: lack of political will and commitment, poor financial support for TB control,
poor organization and management of health services, inadequate human resources, irregular drug supplies, the HIV epidemic, and the
rise of multidrug resistance. An analysis of current operational research on TB is presented on the basis of these constraints, and
examples of successful projects are outlined in the article. We discuss the prerequisites for success, the shortcomings of this WHO-
supported programme, and future challenges and needs.
Keywords Tuberculosis, Pulmonary/prevention and control/drug therapy; Operations research; Health services research; Health
services administration; HIV infections/prevention and control; World Health Organization (source: MeSH, NLM ).
Mots cle´s Tuberculose pulmonaire/pre´vention et controˆle/chimiothe´rapie; Recherche ope´rationnelle; Recherche en sante´ publique;
Administration services de soins; HIV, Infection/pre´vention et controˆle; Organisation mondiale de la Sante´ (source: MeSH, INSERM).
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Introduction
Operational research offers significant gains at relatively low
cost, and in a time frame of months or, at themost, a few years,
but its application to tuberculosis (TB) has been relatively
neglected (1). In this context, we mean operational research
specifically aimed at developing interventions that result in
improved policy-making, better design and implementation of
health systems, andmore efficient methods of service delivery.
It is rooted in national and local experience, but can be applied
at the global, national, or community level. Murray has given
wider definitions of operational research (2). The present paper
argues for greater investment in operational research and
indicates some needs and opportunities for this, focusing on
the approach to operational research taken byWHO following
the development of its new recommended control strategy for
TB, the ‘‘DOTS’’ strategy (3). The marketing of this strategy
began in 1995 (4). Previously, WHO’s efforts in applying
operational research to TB control had been restricted by
relatively low levels of funding to a patchwork of small-scale
studies that were poorly focused and difficult to conduct in
settings without a clear control strategy. Since 1996 WHO’s
operational research on TB has been concentrated in countries
that have begun implementation of the DOTS strategy, and
has focused on global and regional issues through relatively
large-scale multicentre projects.
Progress in operational research in some
key areas
A rational framework is necessary to develop a research agenda
and select priorities when resources are scarce. We have based
our framework on a global analysis, made in 1998, of the reasons
for the persistence of TB and the factors preventing its better
control (5). What follows draws on the results of several
meetings convened by WHO since 1990 with controllers and
researchers from countries with high TB burdens. The aims
were to arrive at an improved definition of the priorities for
research on TB, to develop strategies for addressing them (6),
and to implement programmes of work.
Lack of political will and commitment
The lack of political commitment in governments, development
agencies, and donors was seen as the principal factor hindering
TB control. This matter has to be dealt with primarily at the
political level. However, the priority research response is the
development of convincing arguments for the adoption and
expansion of the DOTS strategy. Because economics is the
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driving force of the political process in most countries, national
or provincial studies of the cost-effectiveness of the DOTS
strategy are essential. In India, for example, a relatively
straightforward analysis of this type (7) demonstrated a net
annual potential gain to the economy of ca US$ 500 million.
Arguments in favour of health interventions that
alleviate poverty are increasingly deployed with a view to
raising health expenditure (1). Direct evidence is often lacking,
although the association of TB with poverty has been noted
and debated for centuries (8). However, now that DOTS
programmes have been in place for several years in various
communities it should be possible to demonstrate their impact,
if any, on social and economic indicators. This could be
undertaken, for example, in China, where DOTS programmes
cover roughly half the country. Specific studies may need to
focus on disadvantaged groups such as women and ethnic
minorities.
Studies of peoples’ perception of the importance of TB
are important, since politicians depend, to a greater or lesser
extent, on support from their populations. Such work is also
crucial for the design of advocacy campaigns seeking to raise
awareness and stimulate political action, i.e. to achieve social
mobilization. A study of the perceived priority of TB in India
(9) showed that its control was severely underfunded, stigma
was common, and the public were ignorant of the causes of and
proper remedies for the disease.
Other fertile areas for research include analysis of the
effectiveness of public health laws and regulations, and case
studies of successful attempts to improve TB control.
Financial constraints
Apart from the need for greater financial resources, there is a
requirement for more efficient spending and for better
transparency and accountability. For the poorest countries,
long-term donor support needs to be negotiated, but every
country should gradually increase its financial commitment to
TB control (1).
The research questions centre on the fact that financial
flows to TB control are often unknown, while the financial and
economic costs, potentials and lost opportunities are not well
quantified. Economic and financial analyses of the costs of
poor TB control and the realistic costs of improved
programmes, as well as of their social and economic benefits,
would greatly aid decision-making (10).
The question arises as to how TB control of high quality
can be financed. As for other diseases of high priority, there are
many options for financing such control, e.g. public provision
through general taxation, publicly supported or private
insurance schemes of various kinds, or direct payment by
patients and their families (11). What is an appropriate level of
public expenditure?Within the public sector, should finance be
delivered via states, regions or provinces, or should it be
provided directly to health districts or hospitals? What types of
incentives, financial or otherwise, might improve outcomes,
and at what levels? These questions cannot be answered unless
it is known how much patients pay as out-of-pocket expenses
or user fees, howmuch public or private insurance cover exists,
and whether the public health system, private-for-profit
practitioners or not-for-profit private institutions are providing
services. If care is publicly provided in the main, is it properly
balanced between salaries, equipment, consumables, main-
tenance and capital expenditure? Is its geographical distribu-
tion equitable? Does it favour the poorest people or is it
subsidizing the middle classes?
Inadequate organization and management
The key factor in terms of organization and management is past
failure by underfinanced public sectors to design effective health
systems and deliver efficient services. The main needs are to
improve the quality of management and to increase the number
of outlets for the provision of TB control services.
Clear descriptions of the consequences of inadequate
services are essential (12). In Africa the need is to design systems
that reach dispersed, mainly rural, populations. Initiatives such
as the Community TB Care in Africa Project (Box 1) aim to
utilize the capacity of communities to support patients with TB
during treatment. In Asia, and increasingly in Africa, the priority
is to improve the performance of the ubiquitous private-for-
profit practitioners (13). In western India, over 80% of patients
with TB are diagnosed by private practitioners and most receive
some or all of their care from these providers (14). Operational
Box 1. The Community Tuberculosis Care in Africa Project (36)
WHO and several partners set up this multinational care project in order
to involve communities in the care of patients with tuberculosis (TB)
and thereby to improve the performance of overstretched national TB
programmes. Specifically, the aim was to reduce periods of hospital
admission, improve case-holding, and reduce default rates by providing
community support to patients during treatment until cure was
achieved. This included direct observation of the initial phase of
treatment.
In each district the intervention included i) identifying and
mobilizing a suitable community organization; ii) developing links
between general health services, national TB control programmes, and
the community organization; iii) training and supervising community
members; iv) adapting recording and reporting systems for use in the
community; v) distributing anti-TB drugs and preventing potential
abuse, particularly of rifampicin; vi) extending the management
responsibilities of national TB control programmes so as to harness the
community contribution to care. Projects were established in
Botswana, Kenya, Malawi, South Africa, Uganda, and Zambia in
urban and rural settings. Study designs included prospective controlled
studies and districts with historical controls. A variety of community
organizations was involved, ranging from parish development
committees to faith-based nongovernmental organizations. Coordina-
tion was undertaken by WHO.
In all the countries, community-based care was effective,
feasible, affordable, and more cost-effective than the previous systems
based on health facilities. Patients generally preferred it. Uganda
rapidly adopted the approach as the national strategy for TB control,
and most of the other countries are modifying their TB control strategies
to include a community-based component. Additional countries not
previously involved are now incorporating community-based care into
their plans for national TB control.
Successful collaboration between general health services,
national TB control programmes, and community health workers was
found to depend on the following: i) good communication links and
referral schemes; ii) good education of TB patients and their families;
iii) training community health workers and health service staff; iv) a
system of regular supervision by staff of national TB control programmes
and general health services. The main challenges in implementing the
intervention were linked to the identification of the leadership
responsible for managing the change process, the development of
management capacity, and the provision of sustainability.
For the future, in settings where high levels of treatment success
are achieved, consideration could be given to the use of similar
community approaches in the identification of suspect TB cases, with a
view to increasing detection rates.
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research projects are showing how private practitioners and
hospitals can work together to improve service provision
(15, 16). Most countries could benefit from pilot approaches
such as these, provided that they are sufficiently large,
sustainable, and coordinated with TB control at national or
state level.
The maintenance of effective TB control while health
sector reforms (e.g. decentralization, integration and privatiza-
tion) are proceeding is a matter of concern to many managers
of national TB control programmes (17). At this stage there is a
need for descriptive work documenting experiences of the
impact of health sector reform on TB control, so that a record
can be built up of what does and does not work (18). There is
nomajor reason why the control of TB should not adapt to the
processes involved in health reform.
A number of important questions have received little
attention. What kinds of health system and methods of service
delivery can control TB in the shifting populations of very large
cities in the developing world? Within the primary health care
system, can the integration of TB control with themanagement
of other lung diseases affecting adults offer increased
efficiency (19)? Why is the rate of case detection so low in
many countries? Answering the last question is a matter of
urgency because of the epidemiological consequences of
delayed diagnosis.
In Africa, TB case notifications are usually high and
services are often overloaded. Patients can slip through the net
because of the difficulty of providing the three sputum samples
required for diagnosis (B. Squire, personal communication,
2002). Attempts to simplify diagnosis using existing tools have
had only limited results and success in this area will probably
have to await the arrival of novel technologies (20). However,
innovativeways should be designed and tested in order to ensure
that diagnosis by means of the tools available at present is as
rapid and complete as possible (21).
Inadequate human resources
In most countries there are insufficient well-trained staff to
provide TB control of adequate quality. For many countries
there is poor documentation of the following: the numbers of
staff needed, their cadre and training levels; the attrition rate,
especially in areas where there is a high prevalence of human
immunodeficiency virus (HIV) infection; the replacement
rates required; and the sources of new staff. There has been
little study of the impact of career structures and the
importance of recognition, rewards, and incentives on staff
retention. It is vital to know what national and international
training schemes are needed to maintain staff numbers, quality
and morale.
A comparison of policies and strategies adopted and
carried out by various countries with different standards of TB
control could be of great value. One key issue of concern is the
impact of merging specific TB control programmes with more
general communicable disease activities, as is happening in
China and many other countries. Strategies for protecting
health workers on wards and in laboratories are of major
importance but far from easy to implement because resources
are often limited (22, 23).
Unreliable anti-TB drug supply
Apart from the limited ability to afford anti-TB drugs, the
major problems relate to ensuring regular supplies of drugs of
high quality. WHO’s essential drugs programmes have been
working in this area for many years and there is now an
improved understanding of the processes for the procurement,
storage, distribution and prescription of anti-TB drugs. STOP
TB recently established the Global Drug Facility in order to
improve the reliability of drug supplies for the poorest
countries (24).
Priority research issues include the need to document
failures of regularity or quality in the supply of drugs.Where the
Global Drug Facility is supplying drugs, how does this affect
TB control and how does it modify the way the system works?
For example, donations made by the Global Drug Facility
might conceivably be matched by equivalent withdrawals of
public funds to be spent elsewhere.
The mechanisms for ensuring drug quality comprise a
further priority area, especially in respect of the fixed-dose
combinations that are increasingly recommended (25). Much
remains to be done to assess more effective ways of delivering
treatment, e.g. blister packaging with fixed-dose combinations
and innovative ways of supporting patients to adhere to
treatment.
Impact of HIV/AIDS
The impact that HIV has had on TB services in sub-Saharan
Africa is well known (26). There is now a similar threat in Asia.
The main problem is how to maintain, let alone improve, the
control of TB in the face of enormous increases in caseload
attributable to HIV. This is arguably the most serious challenge
for the future of TB control. First, surveillance is essential in
order to determine the scale of the problem and plan a response.
Aside from surveys of HIV infection among key affected
groups, it is essential to know the HIV infection rates in patients
with TB. Second, the control of TB in settings with high HIV
infection rates demands measures in addition to those of the
basic DOTS strategy (27).
The principal research issues are therefore the design and
testing of the optimalmix ofmeasures needed at district level for
the direct control of TB (strengthening and expansion ofDOTS,
and intensified case-finding, isoniazid preventive therapy (28))
and interventions to control HIV and, therefore, indirectly, TB
(e.g. voluntary counselling and testing and the provision of
condoms and antiretroviral therapy). The ProTEST Initiative is
a multicentre study designed to show the effectiveness of a
package of such interventions at district level, centred on
voluntary counselling and testing. Thus far, the initiative has
shown that districts can manage such an approach, that demand
for voluntary counselling and testing is enormous provided the
results can be obtained on the day of testing, and that isoniazid
preventive therapy is feasible. Preliminary results suggest that
isoniazid preventive therapy is cost-effective and that voluntary
counselling and testing centres can identify and refer TB
suspects. The impact of behavioural changes brought about
through voluntary counselling and testing as well as final cost-
effectiveness assessments are expected to be known by mid-
2003. Severely affected countries are already requesting an
extension of ProTEST (29, 30). Isoniazid preventive therapy
has been well addressed over the last 10 years but the
intensification of case-finding has been little studied since the
mass radiography campaigns of the early 20th century.
Additional priority areas include ways of reducing the extremely
high mortality among HIV-infected patients treated for TB (31)
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and, particularly, further investigation of the controversial area
of preventive therapy using trimethoprim–sulfamethoxazole
(cotrimoxazole). The greatest hope, however, in the absence of
an HIV vaccine, lies with the provision of antiretroviral therapy
(32). There are various research questions relating to TB: How
efficacious is antiretroviral therapy in the prevention of TB?
How effective is it in the field? What are the best methods of
delivery?
Impact of drug resistance
Current first-line drug regimens are inadequate for the cure of
multidrug-resistant tuberculosis (MDR-TB) (33). Beyond the
accurate surveillance of drug resistance the main question
concerns the management of MDR-TB cost-effectively,
affordably and equitably. WHO’s multicentre DOTS-Plus
project approaches this matter through operational research at
the district level and negotiations at the global level (34, 35). A
consensus has been reached on minimum standards for
treatment programmes confronting multidrug resistance and
huge price reductions have been negotiated with manufacturing
companies (35). Pilot projects are operating in Eastern Europe,
the Russian Federation, South America, and South-East Asia. It
is expected that evidence-based standards for managing MDR-
TB will have been finalized by 2003.
Conclusions
A few large-scale international and national projects with
WHO involvement have begun to answer vital operational
questions relating to TB control. In some instances these
projects have started to improve the performance of control
programmes. The prerequisites for success include a careful
analysis of countries’ needs and of the limiting factors. The
existence of at least a basic DOTS-based TB programme
greatly facilitates operational research. Evaluating and
recording the outcome for each patient is an integral part of
programme evaluation and is also an excellent research tool
for assessing the outcomes of interventions. The integration
of operational research with the work of control programmes,
involving, where possible, the same personnel in both
research and control activities, has resulted in a high output
of information and analysis that can be swiftly applied to
policy and practice, as has been shown in India and Malawi
(Box 2).
However, set against the agenda presented here, these
projects with which WHO is associated make a relatively small
contribution. Moreover, notwithstanding a significant increase
in the amount of operational research conducted and published
through national TB control programmes and other agencies
during the past decade, some priority areas of research have
received scant attention. These include the lack of political
commitment and the inadequacy of financial systems apart from
cost-effectiveness assessments. The problem of human re-
sources in TB control largely remains to be tackled. Most
research, conducted with WHO support or by others, has
focused on service delivery. The cost-effectiveness of opera-
tional research, as compared with other types of research or with
other WHO activities, has not been assessed.
Further progress in operational research relating to TB
requires continuous strategic analysis of impediments to
control. This is the responsibility of WHO as well as its partner
agencies and countries. The next steps that should be taken by
WHO and/or other agencies include the following: develop-
ment of a plan to ensure that sufficient qualified operational
researchers are available in low-income countries; systematic
assessment of training needs (field-oriented training manuals
are planned by WHO); action to bridge the gulf between
disease control personnel and academic researchers; genera-
tion of opportunities for operational researchers to interact
with each other, especially at the regional and country levels;
and provision of adequate funding.
Funding for operational research has probably increased
significantly over the past five years but a shortfall remains. The
successes of TB operational research should be publicized and
donor agencies and national governments should be made
aware of them. The Commission on Macroeconomics and
Health has repeated calls for 5% of project assistance to be
allocated to operational research. Operational research can
answer many of the outstanding questions concerning the
effective implementation of TB control, but only if it is
adequately led and supported by trained and motivated staff
with sufficient funding. n
Conflicts of interest: none declared.
Box 2. Operational research at the national level
Malawi provides the most successful example of a national operational
research programme in the field of tuberculosis (TB) control (37). Health
systems research in TB control began in Malawi in 1994 with the
recognition that the National Tuberculosis Control Programme was in
dire straits: notifications were soaring as the incidence of HIV increased,
cases were diagnosed without adequate investigation, hot spots of
transmission were suspected, and cure rates were poor. With initial
support from WHO, the Malawi College of Medicine and the National
TB Control Programme set up research studies in order to tackle these
problems. The diagnostic process and its shortcomings were analysed
in detail; different screening methods for diagnosis were explored; an
assessment was made of the degree to which health care personnel
were adhering to the guidelines of the national programme; the
association between HIV and TB treatment outcome was defined; and
the prevalence of TB in hot spots such as prisons and health care
institutions was measured. A programme management group was
formed which developed and implemented a strategy on control and
research. Operational research became an integral component of the
National TB Control Programme and the research agenda was firmly
linked to the objectives of its five-year development plan.
Research can be made directly relevant to TB control by making
sure that the questions it poses are linked to constraints and objectives,
thereby enabling its findings to influence policy and practice. For
example, one study showed that over 40% of smear-positive TB
patients spent at least one month with a traditional healer before
attending for orthodox medical care: the national TB control
programme has since trained over 3000 traditional healers in
15 districts. In another example, the incidence of TB among health
care staff was found to be 3.6% per year. As a result the national TB
control programme produced guidelines, for use in every hospital, that
were aimed at reducing nosocomial TB transmission. This close
integration of research with programme activities has attracted further
funds from various donors. Future challenges include designing
collaborative activities with the National AIDS Control Programme and
reducing the incidence of TB despite the high prevalence of HIV
infection.
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Re´sume´
Elargir le champ de la recherche pour ame´liorer la politique de sante´ et la prestation des services et pour
rendre les syste`mes de sante´ plus performants dans le domaine de la lutte contre la tuberculose : point de
vue de l’OMS
La mise en œuvre en 1995 de la strate´gie DOTS de l’OMS pour
lutter contre la tuberculose a conduit a` e´largir, adapter et
ame´liorer la recherche ope´rationnelle dans ce domaine. Partant
d’une mosaı¨que d’e´tudes d’envergure limite´e axe´es sur les
aspects de la prestation des services, la recherche ope´rationnelle a
e´volue´ au profit souvent de projets multipays de plus grande
envergure, englobant aussi politique de sante´ et besoins des
syste`mes de sante´. Les programmes nationaux de lutte contre la
tuberculose tiennent actuellement compte des re´sultats obtenus.
En 1998, un comite´ spe´cial a de´fini les principaux facteurs faisant
obstacle a` l’e´largissement de la strate´gie DOTS : absence de
volonte´ politique et d’engagement, insuffisance des appuis
financiers pour combattre la tuberculose, mauvaise organisation
et gestion des services de sante´, insuffisance des ressources
humaines, approvisionnement en me´dicaments irre´gulier, e´pide´-
mie de VIH/SIDA et augmentation de la polypharmacore´sistance.
On trouvera dans le pre´sent article une analyse de la recherche
ope´rationnelle actuelle compte tenu de ces obstacles ainsi que des
exemples de projets ayant abouti. Y sont e´galement e´voque´s les
pre´alables indispensables pour mener a` bien un projet, les
faiblesses du programme soutenu par l’OMS ainsi que les de´fis et
les besoins futurs.
Resumen
Agenda de las investigaciones orientadas a mejorar las polı´ticas sanitarias, el desempen˜o de los sistemas y
la prestacio´n de servicios para el control de la tuberculosis: perspectiva de la OMS
El desarrollo de la estrategia DOTS de la OMS para el control de la
tuberculosis en 1995 propicio´ la expansio´n, adaptacio´n y mejora de
las investigaciones operativas en ese terreno. De ser un mosaico de
estudios en pequen˜a escala centrados en aspectos de la prestacio´n
de servicios, las investigaciones operativas sobre la tuberculosis
han pasado a ser proyectos en gran escala, a menudo multipaı´ses,
interesados tambie´n por las polı´ticas sanitarias y las necesidades de
los sistemas de salud. Los programas nacionales de lucha contra la
tuberculosis esta´n llevando ya a la pra´ctica los resultados
conseguidos. En 1998 un comite´ especial identifico´ los principales
factores que entorpecen la expansio´n de la DOTS: falta de voluntad
y compromiso polı´ticos, escaso apoyo financiero a la lucha contra la
tuberculosis, mala organizacio´n y gestio´n de los servicios de salud,
recursos humanos insuficientes, suministro irregular de medica-
mentos, epidemia de VIH y aumento de la polifarmacorresistencia.
Se hace aquı´ un ana´lisis de las actuales investigaciones operativas
sobre la tuberculosis en relacio´n con esas limitaciones, y se
presentan sucintamente ejemplos de proyectos exitosos. Anali-
zamos asimismo las condiciones necesarias para el e´xito de esas
iniciativas, las deficiencias de este programa apoyado por la OMS y
los futuros retos y necesidades.
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